PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8226459

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	08/04/2023

CONVEYING PARTY DATA

Name	Execution Date
NARING HEALTH, INC. (F/K/A DISCERNDX, INC.)	08/04/2023

RECEIVING PARTY DATA

Name:	VIOME LIFE SCIENCES, INC.		
Street Address:	205 108TH AVENUE NORTHEAST		
Internal Address:	SUITE 150		
City:	BELLEVUE		
State/Country:	WASHINGTON		
Postal Code:	98004		

PROPERTY NUMBERS Total: 8

Property Type	Number
Patent Number:	9689874
Patent Number:	10867706
Patent Number:	7955810
Patent Number:	11592448
Application Number:	16089019
Patent Number:	11404165
PCT Number:	US2023060918
Patent Number:	9141756

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8609618010

Email: jdouglas@nuventus.com

Correspondent Name: JOEL DOUGLAS

Address Line 1: 13030 BRIDGEFORD AVE

Address Line 2: BONITA SPRINGS

Address Line 4: BONITA SPRINGS, FLORIDA 34135-3447

NAME OF SUBMITTER: JOEL DOUGLAS

PATENT

508179275 REEL: 065263 FRAME: 0637

SIGNATURE:	/joel douglas/
DATE SIGNED:	10/18/2023

Total Attachments: 48

source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page1.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page2.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page3.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page4.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page5.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page6.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page7.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page8.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page9.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page10.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page11.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page12.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page13.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page14.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page15.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page16.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page17.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page18.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page19.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page20.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page21.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page22.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page23.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page24.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page25.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page26.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page27.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page28.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page29.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page30.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page31.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page32.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page33.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page34.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page35.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page36.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page37.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page38.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page39.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page40.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page41.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page42.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page43.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page44.tif

> PATENT REEL: 065263 FRAME: 0638

source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page45.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page46.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page47.tif source=Viome Naring Health Merger Agreement w Patent Schedule (Redacted)#page48.tif

PATENT REEL: 065263 FRAME: 0639

MERGER AGREEMENT

by and among

VIOME LIFE SCIENCES, INC.,

NARING HEALTH, INC. (F/K/A DISCERNDX, INC.),

VIOME NARING MERGER SUB INC.

and

THE COMPANY STOCKHOLDERS NAMED HEREIN

dated

AUGUST 4, 2023

#5428159 v1 / 75684-001

PATENT
REEL: 065263 FRAME: 0640


MERGER AGREEMENT

THIS MERGER AGREEMENT (this "Agreement") is made as of August 4, 2023 by and among Viome Life Sciences, Inc., a Delaware corporation ("Buyer"), Naring Health, Inc. (f/k/a DiscernDx, Inc.), a Delaware corporation (the "Company"), and Viome Naring Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Buyer ("Merger Sub"), and Khosla Ventures Seed C, LP and Khosla Ventures Seed D, LP, each a Delaware limited partnership (each a "Company Stockholder" and together the "Company Stockholders"). Each of the foregoing may be referred to as a "Party" and together as the "Parties."

RECITALS

	A.	WHEREAS,	this Agree	ement conte	nplates a	merger of	the Merger	r Sub with	and into the
Comp	pany, with	the Company	becoming	the Survivi	ng Corpo	ration in ac	cordance v	vith this Ag	greement. In
conne	ection with	n the Merger,							
	(the "N	Aerger Consid	deration")	in accordan	ce with th	ne following	g waterfall,	as set forth	in detail on
Sche	dule A:								
									•

B. WHEREAS, concurrently with the execution and delivery of this Agreement, and as a condition and inducement to Buyer's and Merger Sub's willingness to enter into this Agreement, with respect to each patent license agreement set forth on <u>Subsection 2.9</u> of the Disclosure Schedule, the Company will obtain a consent to assign its rights to the intellectual property described thereunder to the Buyer, which assignment will become effective at the Effective Time.



AGREEMENT

NOW, THEREFORE, in consideration of the representations, warranties and covenants herein contained, the Parties hereby agree as follows.

1. <u>The Merger</u>. Upon and subject to the terms and conditions of this Agreement, the Merger Sub shall merge with and into the Company at the Effective Time. From and after the Effective Time, the separate corporate existence of the Merger Sub shall cease and the Company (in its capacity as the entity surviving the Merger, the "Surviving Corporation") shall continue as the entity surviving the Merger. The Merger shall have the effects set forth in Section 259 of the Delaware General Corporation Law.


1.1 <u>The Closing</u>.

#5428159 v1 / 75684-001

- (a) The closing of the transactions contemplated herein shall take place remotely via the exchange of documents and signatures, at such other time and place as the Buyer, the Company and the Company Stockholders mutually agree upon, orally or in writing (the "Closing").
- (b) At the Closing, the Company shall file with the Secretary of State of the State of Delaware the Certificate of Merger (the time of such effective filing being the "Effective Time").
- (c) At the Closing, the Company and each Company Stockholder, as applicable, shall deliver, or cause to be delivered, to Buyer:
 - (i) an assignment or other transfer document sufficient to transfer the Company Shares to Buyer, duly executed by Company Stockholder;



(iii) a certificate of the Secretary or an equivalent officer of the Company certifying the names and signatures of the officers of the Company authorized to execute this Agreement and any attachments or ancillary documents contemplated under this Agreement; and



1.2 <u>Additional Action</u>. The Surviving Corporation may, at any time from and after the Effective Time, take any action, including executing and delivering any document, in the name and on behalf of either the Company or the Merger Sub in order to consummate and give effect to the transactions contemplated by this Agreement.



The Certificate of Incorporation and By-laws

The Certificate of Incorporation of the Surviving Corporation immediately following the Effective Time shall be amended and restated to be the same as the Certificate of Incorporation of the Merger Sub immediately prior to the Effective Time

The By-laws of the Surviving Corporation immediately following the Effective Time shall be the same as the By-laws of the Merger Sub immediately prior to the Effective Time

1.7 Directors and Officers of the Buyer and the Surviving Corporation.


(a) The directors of the Merger Sub immediately prior to the Effective Time shall be the initial directors of the Surviving Corporation, each to hold office in accordance with the Certificate of Incorporation and By-laws of the Surviving Corporation.

(b) The officers of the Merger Sub immediately prior to the Effective Time

shall be the initial officers of the Surviving Corporation, each to hold office in accordance with the

Certificate of Incorporation and By-laws of the Surviving Corporation.

- 1.11 <u>Defined Terms Used in this Agreement</u>. In addition to the terms defined above, the following terms used in this Agreement shall be construed to have the meanings set forth or referenced below.
- (a) "Action" means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.
- (b) "Affiliate" means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person.
 - (c) "Code" means the Internal Revenue Code of 1986, as amended.
- (d) "Common Stock" means shares of common stock, par value \$0.0001 per share, of the Company.
- (e) "Company Intellectual Property" means all patents, patent applications, registered and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases that are owned or used by the Company in the conduct of the Company's business as now conducted and as presently proposed to be conducted.



- (h) "**Fundamental Representations**" means the representations and warranties contained in Sections 2.1, 2.2, 2.4, 2.5, 2.15, 3.1, 4.1, 4.2, 4.3, 4.4, and 4.5.
- (i) "Governmental Entity" shall mean any nation or government, any state or other instrumentality or political subdivision thereof (including any county or city), any entity exercising executive, legislative, judicial, military, regulatory or administrative functions of or pertaining to government, and any quasi-governmental authority of any nature.
- (j) "Law" means any federal, state, local, foreign or other law, statute, ordinance, regulation, rule, regulatory or administrative guidance, order, constitution, treaty, principle of common law or other restriction of any Governmental Entity.
- (k) "Losses" means losses, damages, liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys' fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; provided, however, that "Losses" shall not include punitive damages, except to the extent actually awarded to a governmental authority or other third party.
- (l) "Material Adverse Effect" means a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, or results of operations of the Company or Buyer, as the case may be.
- (m) "Note Purchase Agreement" means that certain Note Purchase Agreement, dated July 26, 2022 by and among the Company and the Persons listed on the Schedule of Purchasers attached thereto.
- (n) "Person" means any individual, corporation, partnership, trust, limited liability company, association or other entity.



- (r) "Securities Act" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
- 2. Representations and Warranties of the Company. The Company hereby represents and warrants to the Buyer that, except as set forth on the Disclosure Schedule attached as Exhibit A to this Agreement, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the following representations are true and complete as of the date of the Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections and subsections contained in this Section 2, and the disclosures in any section or subsection of the Disclosure Schedule shall qualify other sections and subsections in this Section 2 only to

the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.

For purposes of these representations and warranties (other than those in Subsections 2.2, 2.3, 2.4, 2.5, and 2.6), the term the "Company" shall include any subsidiaries of the Company, unless otherwise noted herein.

2.1 Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect, and each such jurisdiction is set forth on Section 2.1 of the Disclosure Schedules.



- 2.3 <u>Subsidiaries</u>. Except as set forth in Section 2.3 of the Disclosure Schedules, (a) the Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity, and (b) the Company is not a participant in any joint venture, partnership or similar arrangement.
- 2.4 <u>Authorization</u>. All corporate action required to be taken by the Company's Board of Directors and stockholders in order to authorize the Company to enter into this Agreement has been taken or will be taken prior to the Closing. All action on the part of the officers of the Company necessary for the execution and delivery of this Agreement and the performance of all obligations of the Company under this Agreement to be performed as of the Closing has been duly authorized. This Agreement, when executed and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors' rights generally, or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.



2.7 <u>Intellectual Property</u>. The Company owns, licenses, or possesses sufficient legal rights to all Company Intellectual Property without any known conflict with, or infringement of, the rights of others, including prior employees or consultants, or academic or medical institutions with which any of them may be affiliated now or may have been affiliated in the past. To the Company's knowledge, no

product or service marketed or sold (or proposed to be marketed or sold) by the Company violates or will violate any license or infringes or will infringe any intellectual property rights of any other party. Other than with respect to commercially available software products under standard end-user object code license agreements, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Company Intellectual Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights and processes of any other Person. The Company has not received any communications alleging that the Company has violated, or by conducting its business, would violate any of the patents, trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person. The Company has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the Company's business.


Each employee and consultant has assigned to the Company all intellectual property rights he or she owns that are related to the Company's business as now conducted and as presently proposed to be conducted and all intellectual property rights that he, she or it solely or jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting relationship with the Company that (a) relate, at the time of conception, reduction to practice, development, or making of such intellectual property right, to the Company's business as then conducted or as then proposed to be conducted, (b) were developed on any amount of the Company's time or with the use of any of the Company's equipment, supplies, facilities or information or (c) resulted from the performance of services for the Company. Subsection 2.7 of the Disclosure Schedule lists all patents, patent applications, registered trademarks, trademark applications, service marks, service mark applications, tradenames, registered copyrights, and licenses to and under any of the foregoing, in each case owned by the Company.

For purposes of this

Subsection 2.7, the Company shall be deemed to have knowledge of a patent right if the Company has actual knowledge of the patent right or would be found to be on notice of such patent right as determined by reference to United States patent laws. No government funding, facilities of a university, college, other educational institution or research center, or funding from third parties was used in the development of any Company Intellectual Property. No Person who was involved in, or who contributed to, the creation or development of any Company Intellectual Property, has performed services for the government, university, college, or other educational institution or research center in a manner that would affect Company's rights in the Company Intellectual Property.

2.8 Compliance with Other Instruments. The Company is not in violation or default (i) of any provisions of the Company Charter or its Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under any lease, agreement, contract or purchase order to which it is a party or by which it is bound that is required to be listed on the Disclosure Schedule, or (v) to its knowledge, of any provision of federal or state statute, rule or regulation applicable to the Company, the violation of which would have a Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree,

contract or agreement; or (ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company.



#5428159 v1 / 75684-001



(c) Subsection 2.14(g) of the Disclosure Schedule sets forth each employee

11

benefit plan maintained, established or sponsored by the Company, or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security Act of 1974, as amended ("ERISA"). The Company has made all required contributions and has no liability to any such employee benefit plan, other than liability for health plan continuation coverage described in Part 6 of Title I(B) of ERISA, and has complied in all material respects with all applicable laws for any such employee benefit plan.

2.15 Tax Returns and Payments. Except as set forth in Section 2.15 of the Disclosure Schedules, there are no federal, state, county, local or foreign taxes due and payable by the Company which have not been timely paid. There are no accrued and unpaid federal, state, county, local or foreign taxes of the Company which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by any applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and there are in effect no waivers of applicable statutes of limitations with respect to taxes for any year.



has excluded works or inventions from his or her assignment of inventions pursuant to such employee's Confidential Information Agreement. Each current and former employee has executed a non-competition and non-solicitation agreement substantially in the form or forms delivered to counsel for the Buyer.

2.17 <u>Corporate Documents</u>. The Company Charter and Bylaws are in the form provided to counsel for the Buyer. The copy of the minute books of the Company provided to counsel for the Buyer contains minutes of all meetings of directors and stockholders and all actions by written consent without a meeting by the directors and stockholders since the date of incorporation and accurately reflects in all material respects all actions by the directors (and any committee of directors) and stockholders with respect to all transactions referred to in such minutes.



2.19 <u>Insurance</u>. Section 2.19 of the Disclosure Schedule sets forth a true and complete list of each insurance policy maintained by the Company, specifying the insurer, amount of coverage, type of insurance, policy number, and a list of all pending claims. All such insurance policies are in full force and effect. The Company is not in material default with respect to its obligations under any such insurance policies. There are no claims pending under any such insurance policies as to which coverage has been

questioned, denied or disputed or in respect of which there is an outstanding reservation of rights.

2.20 <u>Environmental</u>. The Company is in compliance in all material respects with all Laws related to protection or quality of the natural environment. To the Company's knowledge, it has not become subject to any liabilities under any such environmental Laws, whether by contract or operation of Law, and has not received any written notice from any Governmental Entity or any other Person regarding any actual or alleged violation of such environmental Laws, or any liabilities or potential liabilities under any environmental Law.



- 3. <u>Representations and Warranties of the Company Stockholders</u>. Each Company Stockholder hereby represents and warrants to the Buyer that:
- Authorization. The Company Stockholder has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Company Stockholder, will constitute valid and legally binding obligations of the Company Stockholder, enforceable in accordance with their terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors' rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.



3.3 <u>Disclosure of Information</u>. The Company Stockholder has had an opportunity to discuss the Buyer's business, management, financial affairs and the terms and conditions of the offering of the Buyer Common Stock with the Buyer's management and has had an opportunity to review the Buyer's facilities.

#5428159 v1 / 75684-001



(a) "THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933."

(b) Any legend required by the securities laws of any state to the extent such laws are applicable to the Buyer Common Stock represented by the certificate, instrument, or book entry so legended.

3.7 <u>Accredited Investor</u>. The Company Stockholder is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.



- 3.9 <u>No General Solicitation</u>. Neither the Company Stockholder, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the Buyer Common Stock.
- 3.10 <u>Exculpation Among Company Stockholders</u>. The Company Stockholder acknowledges that it is not relying upon any Person in making its investment or decision to invest in the Buyer.
- 3.11 <u>Residence</u>. If the Company Stockholder is an individual, then the Company Stockholder resides in the state or province identified in the address of the Company Stockholder set forth on <u>Schedule A</u>; if the Company Stockholder is a partnership, corporation, limited liability company or other entity, then the office or offices of the Company Stockholder in which its principal place of business is identified in the address or addresses of the Company Stockholder set forth on <u>Schedule A</u>.
- 4. <u>Representations and Warranties of the Buyer</u>. The Buyer hereby represents and warrants to each Company Stockholder that:
- 4.1 <u>Organization, Good Standing, Corporate Power and Qualification</u>. The Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted. The Buyer is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.



laws.



- (c) The fair market value of the Buyer Common Stock is \$6.68 per share as of the Effective Time, as determined in good faith by the board of directors of the Buyer.
- Authorization. All corporate action required to be taken by the Buyer's Board of Directors and stockholders in order to authorize the Buyer to enter into this Agreement, and to issue the Buyer Common Stock at the Closing has been taken or will be taken prior to the Closing. All action on the part of the officers of the Buyer necessary for the execution and delivery of this Agreement, the performance of all obligations of the Buyer hereunder to be performed as of the Closing, and the issuance and delivery of the Buyer Common Stock has been taken or will be taken prior to the Closing. This Agreement, when executed and delivered by the Buyer, shall constitute valid and legally binding obligations of the Buyer, enforceable against the Buyer in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors' rights generally, or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.




- 4.5 <u>Governmental Consents and Filings</u>. Assuming the accuracy of the representations made by the Company Stockholders in <u>Section 3</u> of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Buyer in connection with the consummation of the transactions contemplated by this Agreement.
- 4.6 <u>Litigation</u>. There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or to the Buyer's knowledge, currently threatened in writing (i) against the Buyer or any officer, director or employees of the Buyer (ii) to the Buyer's knowledge, that questions the validity of this Agreement or the right of the Buyer to enter into this Agreement, or to consummate the transactions contemplated by this Agreement; or (iii) to the Buyer's knowledge, that would reasonably be expected to have, either individually

officers, directors or employees is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or employees, such as would affect the Buyer). There is no action, suit, proceeding or investigation by the Buyer pending or which the Buyer intends to initiate. 5. Indemnification.



For purposes of this Section 5, any inaccuracy in or breach of any (e) representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other similar qualification contained in or otherwise applicable to such representation or warranty.





 $\#5428159\,\mathrm{v1}\,/\,75684\text{-}001$





6. <u>Miscellaneous</u>.

- 6.1 <u>Successors and Assigns</u>. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the Parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the Parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
- 6.2 <u>Governing Law</u>. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware.
- 6.3 <u>Counterparts</u>. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, *e.g.*, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
- 6.4 <u>Titles and Subtitles</u>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
- Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient's next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective Parties at their address as set forth on the signature page or Schedule A, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Subsection 6.6. If notice is given to the Buyer, it shall be sent to 205 108th Ave NE Suite 150, Bellevue, WA 98004, Attention: Chief Executive Officer; and a copy (which shall not constitute notice) shall also be sent to Karr Tuttle Campbell, 701 Fifth Avenue, Suite 3300, Seattle, WA 98104 Attn: Adam D. Matherly.

- 6.9 <u>Amendments and Waivers</u>. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Buyer, the Company and the Company Stockholders.
- 6.10 <u>Severability</u>. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.
- 6.11 <u>Delays or Omissions</u>. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.
- 6.12 <u>Entire Agreement</u>. This Agreement (including the Exhibits hereto) constitutes the full and entire understanding and agreement between the Parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the Parties are expressly canceled.



[Signature Page Follows]

#5428159 v1 / 75684-001

PATENT REEL: 065263 FRAME: 0664 (227.0149)

IN WITNESS WHEREOF, the Parties have executed this Merger Agreement as of the date first written above.

NARING HEALTH, INC.
By: Robbie Schwistzer Name: Robbie Schwietzer
Name: Robbie Schwietzer Title:
VIOME NARING MERGER SUB INC.
By:Name: Naveen K. Jain
Title: Chief Executive Officer
VIOME LIFE SCIENCES, INC.
By:
COMPANY STOCKHOLDERS:
KHOSLA VENTURES SEED C, LP By: Khosla Ventures Seed Associates C, LLC, a Delaware limited liability company and general partner of Khosla Ventures Seed C, LP
By:
KHOSLA VENTURES SEED D, LP By: Khosla Ventures Seed Associates D, LLC, a Delaware limited liability company and general partner of Khosla Ventures Seed D, LP
By:

PATENT REEL: 065263 FRAME: 0665

IN WITNESS WHEREOF, the Parties have executed this Merger Agreement as of the date first written above.


NARING HEALTH, INC.				
By:				
Name: Robbie Schwietzer				
Title:				
VIOME NARING MERGER SUB INC.				
Propriet in the interest of the control of the cont				
By: Naveen & Jain Name: Naveen K. Jain				
Title: Chief Executive Officer				
VIOME LIFE SCIENCES, INC.				
DocuSigned by:				
By: Name: Naveen K. Jain				
Name: Naveen K. Jain				
Title: Chief Executive Officer				
COMPANY STOCKHOLDERS:				
COMMETALVE DE COMMEDIDADA				
KHOSLA VENTURES SEED C, LP				
By: Khosla Ventures Seed Associates C, LLC, a				
Delaware limited liability company and general				
partner of Khosla Ventures Seed C, LP				
By:				
Name: John Demeter				
Title: General Counsel				
KHOSLA VENTURES SEED D, LP				
By: Khosla Ventures Seed Associates D, LLC, a				
Delaware limited liability company and general				
partner of Khosla Ventures Seed D, LP				
By:				
Name: John Demeter				
Title: General Counsel				

PATENT REEL: 065263 FRAME: 0666 _ 29 of 49


IN WITNESS WHEREOF, the Parties have executed this Merger Agreement as of the date first written above.


NARING HEALTH, INC.				
By:				
Name: Robbie Schwietzer				
Title:				
VIOME NARING MERGER SUB INC.				
D				
By:				
Title: Chief Executive Officer				
Title. Chief Executive Officer				
VIOME LIFE SCIENCES, INC.				
VIONE EN ESCIENCES, INC.				
By:				
Name: Naveen K. Jain				
Title: Chief Executive Officer				
COMPANY STOCKHOLDEDS.				
COMPANY STOCKHOLDERS:				
KHOSLA VENTURES SEED C, LP				
By: Khosla Ventures Seed Associates C, LLC, a				
Delaware limited liability company and general				
partner of Khosla Ventures Seed C, LP				
DocuSigned by:				
022				
By:				
Name: John Demeter				
Title: General Counsel				
TATOOL A MENTALDEG GEED D. L.D.				
KHOSLA VENTURES SEED D, LP				
By: Khosla Ventures Seed Associates D, LLC, a				
Delaware limited liability company and general partner of Khosla Ventures Seed D, LP				
DocuSigned by:				
By:				
Name: John Demeter				
Title: General Councel				

PATENT REEL: 065263 FRAME: 0667_e30.of49



PATENT REEL: 065263 FRAME: 0668 (231:0749)





PATENT REEL: 065263 FRAME: 0670_{E33 of 49}

PATENT REEL: 065263 FRAME: 0671 (1934-0149)

EXHIBIT A

DISCLOSURE SCHEDULE

This Disclosure Schedule is delivered pursuant to the Merger Agreement (the "Agreement"), by and among Naring Health, Inc. (the "Company"), Viome Life Sciences, Inc., a Delaware corporation (the "Buyer"), and Viome Naring Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Buyer ("Merger Sub"), and the stockholders of the Company listed on Schedule A to the Agreement. All capitalized terms used but not defined herein shall have the meanings as defined in the Agreement, unless otherwise provided.

The section numbers below correspond to the section numbers of the representations and warranties in the Agreement; <u>provided</u>, <u>however</u>, that any information disclosed herein under any section number shall be deemed to be disclosed and incorporated into any other section number under the Agreement where such disclosure would be appropriate and such appropriateness is reasonably apparent from the face of such disclosure.

Nothing in this Disclosure Schedule is intended to broaden the scope of any representation or warranty contained in the Agreement or to create any covenant. Inclusion of any item in this Disclosure Schedule (1) does not represent a determination that such item is material or establish a standard of materiality, (2) does not represent a determination that such item did not arise in the ordinary course of business, (3) does not represent a determination that the transactions contemplated by the Agreement require the consent of third parties, and (4) shall not constitute, or be deemed to be, an admission of liability or an admission against the Company's interest.

References to any document are to such document as amended as of the date of the Agreement, provided such amendment is properly noted in the reference to such document. All descriptions in this Disclosure Schedule of documents that have been previously delivered or made available to the Purchasers or their counsel are qualified in their entirety by reference to the actual documents.

#5428162 v1 / 75684-001

Section 2.1 Other Jurisdictions

- 1. Naring Health, Inc: maintains a business qualification in California.
- 2. Foodome Inc. maintains a business qualification in Massachusetts.

Section 2.3 Subsidiaries

The Company owns 100% of the capital stock of Foodome Inc., a Delaware corporation.



Section 2.7 Intellectual Property.

1. **Patents**: See attached.



PATENTS

Filed	Application Number	Country	Patent No. (P) or Serial No. (S)	Date	Name of Inventor	Title of Invention

PATENT APPLICATIONS

Filed	Application Number	Country	Patent No. (P) or Serial No. (S)	Date	Name of Inventor	Title of Invention

PCT PATENT APPLICATIONS

TETTIMENT MI BIENTIONS							
Filed	Application Number	Country	Patent No. (P) or Serial No. (S)	Date	Name of Inventor	Title of Invention	

Chinese PATENT APPLICATIONS

ennese i i i i i i i i i i i i i i i i i i							
Filed	Application Number	Country	Patent No. (P) or Serial No.	Date		Title of Invention	
			(S)		Name of Inventor		
09/05/2018	201880071886.5	CN				Methods for computational analysis of biological samples with machine learning analysis	
					Brian K. Maples	and systems for same	

Section 2.9(a) Material Contracts.

- 2. Sponsored Research Agreement (BWH Agreement No. 2020A004048), dated as of September 1, 2020, by and among Foodome Inc. and The Brigham and Women's Hospital, Inc., a not-for-profit Massachusetts corporation, as amended by (1) First Amendment to Sponsored Research Agreement, dated August 27, 2021, (2) Second Amendment to Sponsored Research Agreement, dated February 28, 2022, and (3) Third Amendment to Sponsored Research Agreement, dated October 4, 2022.
- 3. Clinical Research Organization Master Services Agreement, dated as of October 5, 2022, by and among 10343781 Canada Inc dba Dicentra CRO, an Ontario corporation, and the Company.
- 4. University Industry Sponsored Research Agreement, dated as of May 6, 2020, by and among Foodome Inc. and Northeastern University, a non-profit institute of higher education.
- 6. License Agreement, dated May 21, 2021, by and among Northeastern University, as Licensor, and Foodome Inc. as Licensee.
- 7. Exclusive Patent License Agreement, dated as of May 2, 2016, by and among the University of Southern California, a California nonprofit corporation, as Licensor, and the Company as successor in interest to Applied Proteomics, Inc., as Licensee.






#5428162 v1 / 75684-001

PATENT REEL: 065263 FRAME: 0681_e45.of49



 $\#5428162\,\mathrm{v1}\,/\,75684\text{-}001$

#5428162 v1 / 75684-001



#5428162 v1 / 75684-001

PATENT REEL: 065263 FRAME: 0685 (249 of 49)

PATENT REEL: 065263 FRAME: 0686 SCHEDULE 2.7
(Patent Docket)

				(Patent Docket)					
Entity (Licensed Fromi Discussible	Northeastern (NE) Coset	Country	Application Status	Application No.	Piling Date 78-May-2009	Pagent No. 1955 830	Essue Date Of-Inn-2001	Expiration Date	Application Title exercise exercises of septem processes for processes, what yes
oodone INE	INV-17069	00 00 06	NSCOO NSCOO ISSUED	13003310 11003000 15909946	20-06-20-0 33-00-003 29-Mar-2018	\$150.758 (0.600.00 11.404.165	2000-0045 2000-0006 02-Aug-2022	N-040-00-1 31-596-904 29-Mar-2038	NOTIFIES AND CONDUCTOR OF SAME AND CONTROL OF CONTROL O
Nacena Dis Discens Dis Discens Dis		68 68 69	ISSUED TO BE ABAND	15/05/27/46 15/05/47/67 1877/87/21 3	33-Dec-2019 08-Abr-2019 05-Sen-2018	11,592,448 9,689,874	28-Feli-2023 27-Feli-2027	29-Aug-2019 08-Aug-2096	TA NOBER EINTER CRITICA ENGINE: THE ARE ONLY THE PROPERTY OF A STATE OF THE STATE O
Discern Dx Discern Dx Discern Dx		EP CN CN		18779128.0 201780033795.8 201780036282.2	05-Sen-2018 31-Mar-2017 11-Apr-2017				MARKER ANALYSIS ROR QUALITY CONTROL AND DISEASE DETECTION INOMARKER DATAINASE GENERATION AND USE MASS SPECTROMETRIC DATA AMALYSIS WORKFLOW
Discern Dx Discern Dx Discern Dx		IN CN CN		201817041006 201880071683.6 201880088625.4	31-May-2017 05-Sep-2018 05-Dec-2018				SIGMAPKER DATALASE GENERATION AND USE MARKER ANALYSIS FOR QUALITY CONTROL AND DISEASE DETECTION ALARGE-SCALE AND ROBLET DIREM STUDY OF COLORECTAL CANCER BIOMARKERS
	fNV-20962	us cw pct	PUBLISHED PUBLISHED PUBLISHED	16000010 2015800118865 PCCC082021016865	27 Sen 2018 02 Sen 2018 02 Feb 2021				GOSSARDZ (LV JAGASZ ZARTEKUTEK A DOLDE) JOGENAZDE GADE MOBRISEN JOSENSARD JAKO DANGABA (1990) SKO BAGARI ARIT MERIKUDI JOGO TUNIKE ERISUPIDI DIRBODIK ARIT ERISUZADIKA ERISUZADIKA ARIT ERISUZADIKA ARIT ERISUZADIKA E
Spice Walk	Continuation in Pari	COP CG CG	PENDING PENDING PENDING	12/96-165 12/96-165 12/96-251	20-Nov-3021 20-Nov-2021				POLYMONIA A RODALTORIA PLATEETTINOON OTMOGRA DIEDE PRITTERE AND RANDO ONIGERSONTER ACTOR PRINTERE
occore/WSOR	INV-37969	08 68 68		17/809/500 83/300/807 83/33/14/3	28-Tue-2022 39-36(-2022 35-Ab)-2022			-15-Abr-2023	Exploración para exploración Secondar Para finales Secondar Para finales Secondar Para finales Secondar Para finales Secondar para finales propositiones de la constanción de la constanci
Foreign MSGR Sconds Sconds		PCT US	PENDING PENDING	65/350 A40 6Ctrt-826/38066618 61/366.028	15-Aur-2022 19-14st-2025 20-5ul-2010			13-Abr 3025	DECIC EXAMENDES MOTORES PRIMERS. METROC STRE SEMETO, CRISTO, SEMES SEMES DE PERSONCIAL CAMPED VITH 46/CTIPIE CAMPINE ANNOSIS AN MOTTE SEALE COMPLEX EXTENSE TRANSCISCIO, MAY ANALYSIS OF RESINOSE TO TREMARY. METROC REF EXTLIATION OF PERSONNE OF OR SEN OF COLOM PACTULATION OF PERSONNE TO TREMARY.
Discern Dis Discern Dis Discern Dis		US US US		61/132.004 61/132.000 61/132.979	30-Nov-2012 30-Nov-2012 05-Mar-2013				METHOU FAX EXAMINATION OF PRESENCE OF OR SINGLE COLUMN PLOTS WETHOUR REP EVALUATION OF PRESENCE OF OR SINGLE OCCUPY WITH ALCORTHMS METHOUR REP EVALUATION OF PRESENCE OF OR SINGLE OCCUPY NO. 175 WORTH ROUMARDER PROFILES FOR PLANDAGING OR NO.20 WORTH ROUMARD OR NO.20 W
Discern Dx Discern Dx Discern Dx Discern Dx		US US US		60/05/835 60/00/265 60/143/635	28-Mar-2014 30-May-2014 23-Jan-2015 06-Apr-2015				PROTEIN ECHINOCEN FOOLES YND DIGWODSHOCKNER'S PROTEIN ECHINACES PROCEEDS YND DIGWODSHOCKNER'S PROTEIN ECHINACES PROCEEDS YND DETECTION COLORECTAL TUNKES PROTEIN ECHINACES PROCEEDS ERE DETECTION COLORECTAL TUNKES PROTEIN ECHINACES PROCEEDS THE TUNKES PER ASSENCE PROTEINS CONTRACTAL TUNKES PROTEINSE PLACE DIGGOVERY THE PER KASSENDE PROTEINS CONTRACTACH CHARNE EXPECTATION VALUES.
Discern Dis Discern Dis Discern Dis		US US		62/141 646 62/141 675 62/141 676	06-Apr-2015 06-Apr-2015 06-Apr-2015				704 961s 81 AUSMINN
Discers Dis Discers Dis Discers Dis		US US		62/143 683 62/143 705 62/143 712	06-Apr-2015 06-Apr-2015 06-Apr-2015				CALCULATION FOR VIIN ASSIGNABLE PROTEINS QC FEAR CLETERINGFRIGHT MS29
Discern Da Discern Da Discern Da		US US US		60/143.718 60/143.725 60/143.737	06-Apr-2015 06-Apr-2015 06-Apr-2015				DALTY OC ANALYSIS METRICS MIST NORMALIZATION PASTERIZATION OF MIST DATA
Discern Dis Discern Dis Discern Dis		US US		62/143-739 62/143-742 62/143-746	06-Apr-2015 06-Apr-2015 06-Apr-2015				DETERMINING LOCATION OF A PEAK PICKUR. MST PEATURE (SOCIETY PETERING AND DECONVOLUTION MST PEATURE (SATIY).
Discern Dix Discern Dix Discern Dix		US US US		62/143/972 62/143/977 62/143/986	06-Aor-2015 07-Aor-2015 07-Aor-2015				ASSISSAMINY OF EXCEPTIONIONION ATROVANYLATION COMMENT SEARCH INCIDENCE CONTROL INTERPACE EXTRACTING TANDEM ANSI SHEETING WORLD A CAYA PROCESSING SYSTEM
Discern Dx Discern Dx Discern Dx		US US US		62/14/1982 62/144/025 62/144/115	07-Apr-2015 07-Apr-2015 07-Apr-2015				OOMPITE A CORPRECTION TO TAKEEN MASS SPECTE A MSL VALUES CONVERSION OF DATA TO API MSL BATA. MASS DEPOTT PROASSITY.
Discers Ds Discers Ds Discers Ds		US US US		62/144-129 62/144-151 62/144-168	07-Apr-2015 07-Apr-2015 07-Apr-2015				RETENTION TIME BILLERING. PROSS SAMPLE MEI PERK CULTIFERING CROSS FRACTIONATION MSJ PERK CULTIFERING SASSISSINITO MEIST TERKS STRACTIONATION PERCENTATION PERPENANCE SASSISSINITO MEIST TERKS STRACTIONATION PERCENTATION PERPENANCE
Discern Ds Discern Ds Discern Ds	000000000000000000000000000000000000000	US US		62/144.185 62/144.202 62/146.158	07-Anr-2015 07-Anr-2015 10-Anr-2015 12-May-2015				ASSISSAMENT OF 1863 T (ROGS TR ACTIONATION) PRACTIONATION PERPERMANCE WAS PERTURE REGISTRACTION PROTEIN GENERALIZE TRANSPER DETECTING COLORECTAL CANCER PROTEIN GENERALIZE TRANSPER DE CETESTING COLORECTAL CANCER PROTEIN GENERALIZE TRANSPER DE CETESTING ADVANCED COLORECTAL ADENDANS.
Discern Da Discern Da Discern Da Discern Da		US US US		627.60.560 627.60.846 627.96.889 627.97.71	32-May-2015 24-May-2015 24-May-2015 09-Oct-2015				PROTEIN BOUAGNEDS ROCELLES DE BEINFETTING AUVANCED COCCIDENT AL JABROWAS. PROTEIN BOUAGNEDS PROCELLES DE BEINFETTING OCCUPIENT, AL CANCER AU PROTEIN BOUAGNEDS PROCELLES DES BEINFETTINGS OCCUPIENT, AL CANCER AUG. ADVANCED AUBHOWA PROTEIN BOUAGNEDS PROCELLES DES BEINFETTINGS OCCUPIENT, AL CANCER AUG. ADVANCED AUBHOWA PROTEIN BOUAGNEDS PROCELLES DES BEINFETTINGS OCCUPIENT, AL CANCER AUG. ADVANCED AUBHOWA PROTEIN BOUAGNEDS PROCELLES DES BEINFETTINGS OCCUPIENT, AL CANCER AUG. ADVANCED AUBHOWA ROTEIN BOUAGNEDS PROCELLES DES BEINFETTINGS PROTEIN BOUAGNESS PROCELLES PROCELLES BEINFETTINGS PROTEIN BOUAGNESS PROCELLES BEINFETTINGS PROTEIN BOUAGNESS PROCELLES BEINFETTINGS PROTEIN BOUAGNESS PROCELLES BEINFETTINGS
Discern Dis Discern Dis Discern Dis Discern Dis		US US US		60/219/11 62/315/862 62/321/098 62/321/099	31-Mar-2016 11-Aor-2016 11-Aor-2016				MONTHS BUILDINGS WOULDS VIRTURED INTHIS COLUMNICAL CAREEY AND ADVANCED ADDROGNA. MONTHS AND EXAMINATION METHODS WE PROCESSING PACK DO AND OSE PROPES
Discers Dx Discers Dx Discers Dx		US US US		62521.009 62521.102 62521.104 62521.116	71-Apr-2016 71-Apr-2016 71-Apr-2016				CENTIO AND USE SERVICES STREMENTS AND TRESHMICAL ERRORS PRINCIPION AND RETENTION THAT ERRORS PRINCIPION ASSESSMENTS PRINCIPION THAT PRINCIPION ASSESSMENTS PRINCIPION THAT PRINCIPION ASSESSMENTS PRINCIPION THE PRINCIPION ASSESSMENTS PRINCIPION ASSE
Discere Dis Discere Dis Discere Dis		US US US		60/605 711 60/664 221 60/654 597	07-Oct-2016 09-Jan-2017 03-Feb-2017				PROTEIN ECONARISER NAVELS RIZ DETECTING COLUPBICTAL CANCER AND ADVANCED ADENOMA BIOMARKIER DATAINASE COMERATION AND USE: BIOMARKIER DATAINASE COMERATION AND USE:
Discern Ds Discern Ds Discern Ds		US US		62/464.047 62/473.198 62/473.548	27-Feb-2017 14-Mar-2017 23-Mar-2017				QUALTY CONTROL PROTOCOL PROTOCOMICS PLATFORM COMEDING STADE SOTOPE STANDARD PEPTITES WITH HIGH PESOLUTION MASS SPECTROMETRY TO
Discern Dix Foodorus Discern Dix		US US US		60496.332 60499.289 60483.123	34-Mar-2017 30-Mar-2017 07-Apr-2017				QUALITY CONTRICE PROCEDURE FOR A PROTEOMOSS PLATFORM PRODOME PLATFORM CYRCING PATOUR SYNDROME PANEL DEVELOPMENT
Discern Dix Discern Dix Discern Dix		US US		62/490 183 62/514/502 62/514/503	26-Apr-2017 02-Jun-2017 02-Jun-2017				A MULTIPLEXED IMMENOLSS AY FOR MEASURING COLORECT ALC ANCER RELATED PROTEINS IN FRIMAN PLAS. WASS SPECTROMETRY-6-ASED TARGETED QUANTIT ATIVE ASSAY FOR USE INTHETERMENTACION OF A REYNDROSTY A PAROCICE COMMENT OF A REYNDROSTY A PAROCICE COMMENT OF A SHOULD METHOR ASSAY.
Discere Dx Discere Dx Discere Dx		US US US		62/519.294 62/524.296 62/534.433	34-Jun-2017 23-Jun-2017 05-Sep-2017				ANDBM/DENTRICATION ENGINE COCCUMENT NO VALUCATION OF COLLERCITAL CANCENCIA CLASSIFIED IN A NEW BLOCK TEST WITH IMPROVED COMUNITY CONTROL MARKERS FOR SAMPLE ANALYSIS
Discers Ds Discers Ds Discers Ds		US US US		60/554-435 62/554-437 62/554-441 62/554-444	05-Sen-2017 05-Sen-2017 05-Sen-2017				SIGNARIZE ANALYSIS FOR DESCASE DETECTION METRICS AND APPRAINALISES RELECTED TO DESCRIPTION AND CORPORATION OF HEALTH COMMITTON AUTOMATED SAMPLE WORKFLOW ONTING TOTAL STREET, AND
Discord Dis Discord Dis Discord Dis		US US		62/554.445 62/554.446	05-Sen-2017 05-Sen-2017 05-Sen-2017				AUTOMATED TEST CHEIPERY SYSTEM AUTOMATED COMPITATIONAL WORKSOWS FOR DATA ANALYSIS QUALITY CONTROL ON MARKED EVELLOWING QUALITY CONTROL ON MARKED EVELLOWING
Discern Dis Discern Dis Discern Dis Discern Dis		US US		62/559 309 62/559 335 62/560 066 62/560 068	15-Sep-2017 15-Sep-2017 18-Sep-2017 18-Sep-2017				GREAT FOOT INCOME MINISTER DELEGATION OF THE TOTAL CONTINUENCE OF THE STATE OF THE
Oscern Dx Oscern Dx Oscern Dx		US US		62/5(0) (0) 1 62/5(8) 192 62/5(8) 194	18-Sep-2017 04-Oct-2017 04-Oct-2017				AUTOMATED COMPUTATIONAL WORKELOWS FOR DATA AWALYSTS. AUTOMATED SAMPLE WORKELOW GATTHO STEDY PLANNON AND ANALYSES.
Discern Dx Discern Dx Discern Dx		US US US		62/968.197 62/968.241 62/94.941	04-Oct-2017 04-Oct-2017 05-Dec-2017				ASTERMATED COMPRIATORIAL WORKELOWS FOR DATA AWALYSTS AUTOMATED TEST DELIVERYS SYSTEM A LARGE: SEX ALS REGISTS OWER STILLY OF COMPRICTAL IS ANOTH BOMARKERS
	INV-19077 INV-19054	US US US	EXPIRED EXPIRED	62/92/168 62/852/800 62/864/172	35 Jan 2019 24-May-2019 20-Jun-2019			24-May-2020 20-Yen-2020	METHODS AND SYSTEMS FOR DETECTING UYER DISEASE CHEMICAL DISEASE PERTURBATION RANKING DRUG-FOOD INTERACTION PREDICTION
Discens Dis Discens Dis Discens Dis		US US		62/913-083 63/036-333	03-Jul-2019 09-Oct-2019 08-Jun-2020				REALTH ASSESSMENT AND BIOMARKER DISCOVERY SISMO COMPUTER VISION METHODS AND PARES, FOR EVALUATING METHODS: DISCOVERY SAND CONDITIONS COLORISTAL CANCER BIOMARKER PAPELS.
Discere Da Foodorse Foodorse		US PCT PCT		63/056/469 PCT/US20/34299 PCT/US2000/038681	24-Jul-2020 22-May-2020 19-Jun-2020				PIELATO ESSESSIMENT, AND BIOLAGENERS DISCOVIDEY SONIA COMPUTER YESON CHEMICAL DOSASS PRETURBATION RANGING DRIGGYCOOK PREMACTION PREDICTION
Discern Dis Discern Dis Discern Dis		KR BR SG		10:2015:7017551 11:20150126162 11:2015042410	02-Dec-2013 02-Dec-2013 02-Dec-2013				METIKO, POR EVALULATION OF PRISENCE OF OR RESIGNOR COLOR TRACORS METIKO, POR EVALULATION OF PRISENCE OF OR RESIGNOR COLOR TRACORS METIKO, POR EVALULATION OF PRISENCE OF OR RESIGNOR COLOR TRACORS METIKO, POR EVALULATION OF PRISENCE OF OR RESIGNOR COLOR TRACORS
Discera Dx Discera Dx Discera Dx		EP US		11201608053P 13858410.7 14094.594	02-Dec-2013 02-Dec-2013				PROTERN BLOGARIKER FROPELES FOR DETECTION COLUPRECTAL TURKINGS METINED KINE PYALLIATION OF PRESENCE OF OR PISK OF COLUP TURKINGS METINED RICE EYALLIATION OF PRESENCE OF OR RISK OF COLUP TURKINGS METINED RICE EYALLIATION OF PRESENCE OF OR RISK OF COLUP TURKINGS METINED RICE EYALLIATION OF PRESENCE OF OR RISK OF COLUP TURKINGS
Discers Dx Discers Dx Discers Dx		US US		14/526-181 14/526-221 14/526-265 14/526-282	28-Oct-2014 28-Oct-2014 28-Oct-2014 28-Oct-2014				METING THE EVALUATION OF PRESENCE OF A WISK OF SOLICA TRANSIS METING THE PALILIATION OF PRESENCE OF A WISK OF SOLICA TRANSIS METING THE EVALUATION OF PRESENCE OF A WISK OF SOLICA TRANSIS METING THE EVALUATION OF PRESENCE OF A WISK OF SOLICA TRANSIS METING THE PALILIATION OF PRESENCE OF A WISK OF SOLICA TRANSIS METING THE PALILIATION OF PRESENCE OF A WISK OF SOLICA TRANSIS
Discere Dis Discere Dis Discere Dis		US US		15/900.241 15/900.241 15/914.456 15/622.340	28-Sen-2016 24-Jan-2017 14-Jun-2017				PROTEIN BOUMBROW PROFILES FOR DETECTING COLORIETAL TUMORS. PROTEIN BROMBINED FAMILES FOR DETECTING COLORIETAL CANCIDA AND ADVANCED ADBROWN. WETROO FOR ENALISATION OF RESIDENCE OF OR SETS OF COLOR TUMORS.
Discera Da Discera Da Discera Da		US EP US		15629.593 15770182.2 16092.434	21-Jun-2017 27-Mar-2015 09-Oct-2018				PROTISM GIOMARKER PAMELS FOR DETECTING COLUMENTAL CANCER AND ADVANCED ADENDARA PROTISM GIOMARKER PROFILES FOR DETECTING COLUMENTAL TLAKERS MASS SPECTROMETRIC DATA AMALYSIS WORKFLOW
NicernDx NicernDx NicernDx		US US		16/400.257 16/66/109 16/64/109	01-May-2019 03-May-2020 03-May-2020				PROTEIN BIOMARKER PANELS VER DETECTING COLORECTAL CANCER AND ADVANCED ADENOMA MARKER MALLYSS FOR QUALITY CORTROL AND DISEASE DETECTION AUTOMATIC JUMPLE WORKFLOW SATING AND DATA ANALYSIS
Discern Dx Discern Dx Discern Dx	00000000000000	US EP US		16719394 16717390.6 17/062.263	03-Jun-2020 08-Aur-2016 02-Oct-2020				ROBURT FAMELS OF COLEMENTAL CANCER BIOMARKERS FORTEN BIOMARKER FAMELS FOR DETECTING COLEMENTAL CANCER AND ADVANCED ADENDMA MICITEN BIOMARKER FAMELS FOR DETECTING COLUMBETAL CANCER AND ADVANCED ADENDMA
NiceraDx NiceraDx NiceraDx		GB GB		17/546-632 1705773-0 1705836-7	09-Dec-2021 08-Apr-2016 09-Mar-2017	GB2545361 2551415	24-Jan-2018 04-Jan-2018		MASS SPECTROMETRIC OMFA, ANALYSIS WORKFLOW PRETIENT BEGINNERS PARKELS FUR DETRECTING COLORBICTAL CANCER AND ADVANCED ADENOMA PROTECTION ECONOMICS PARKELS FUR DETRECTING COLORBICTAL CANCER AND ADVANCED ADENOMA PROTECTION ECONOMICS PARKELS FUR DETRECTING COLORBICTAL CANCER AND ADVANCED ADENOMA.
Noers Ds Noers Ds Noers Ds		EP EP		17720901 8 17723541 3 17793466.4	31-Mar-2017 31-Apr-2017 06-Oct-2017				SIGNAMEDE DATALAGE CONTRACTION AND USE MICES BITCHOUTHER CASA ANALY YES WERRICHES PROTEIN EGNAMATES PARKET STATE OFFICE FOR COLUMNICAL CANCER AND ADVANCED ADDINAGE PROTEIN EGNAMATES PARKET STATE OFFICE FOR COLUMNICAL CANCER AND ADVANCED ADDINAGE PROTEIN EGNAMATES PARKET STATE OFFICE FOR COLUMNICAL CANCER AND ADVANCED ADDINAGE PROTEIN EGNAMATES PARKET STATE OFFICE FOR COLUMNICAL CANCER AND ADVANCED ADDINAGE PROTEIN EGNAMATES PARKET STATE OFFICE FOR COLUMNICAL CANCER AND ADVANCED ADDINAGE.
Oscern Du Oscern Du Oscern Du		GB HK HK		1808422.8 18107827.4 18130284.4 18930660.0	23-May-2018 15-Jun-2018 08-Apr-2016	1248316	15 Nov-2019		PROTEIN HIGHARISTE PARIELE SYGE EFFECTION COLUMENTAL CANDER AND ADVANCES ADBROGA. PROTEIN HIGHARISTE PARIELE SYGE EFFECTION COLUMENTAL CANDER AND ADVANCES ADBROGA. PROTEIN HIGHARISTE PARIELE SYGE EFFECTION COLUMENTAL CANDER AND ADVANCES ADBROGA. PROTEIN HIGHARISTE PARIEL SYGE EFFECTION COLUMENTAL CANDER AND ADVANCES ADBROGA. PROTEIN HIGHARIST OF COLUMENTAL CANDER BIONARKERS.
Ascern Dix Ascern Dix Ascern Dix Ascern Dix		CA CA CA		18821969.9 2.893.158 2.943.827 2.982.169	05-Dec-2018 02-Dec-2013 27-Mar-2015 08-Apr-2016				METRO OR BUSINESS ACCUMENTACION REPORTANCIA METRO OR BUSINESS ACCUMENTACION DE PROPERTIES DE LA CONTRACTION RECORDANCE MODELLA CONTRACTACION RECORDANCE MODELLA CONTRACTACION DE LA CONTRACTACION DEL CONTRACTACION DE LA CONTRACTACION DEL CONTRACTACION DE LA CONTRACTACION DEL CO
NiceraDx NiceraDx NiceraDx NiceraDx		AU CN JP		2982 169 2013351947 201380071930 X 2013 345904	02-Dec-2013 02-Dec-2013 02-Dec-2013	24.201380071930	03-Sen-2019		MOTIFIED RECEIVANCES VANCES FAIR DE POLITING COLOMBICIAL CURRICUM AND ADDRAWLED AUGMENTAIN. MITTINGO RISE PRAILIATION OF PRESENCE OF CREW RISK OF COLON TRANSPE METRICO RISE PRAILIATION OF PRESENCE OF CREW RISK OF COLON TRANSPE METRICO RISE PRAILIATION OF PRESENCE OF CREW RISK OF COLON TRANSPE METRICO RISE PRAILIATION OF PRESENCE OF CREW RISK OF COLON TRANSPE
Nicera Dx Nicera Dx Nicera Dx		AU CN IN		201502229 20150028098.4 201617036962	21-Mar-2015 21-Mar-2015 21-Mar-2015				PROTIEN ENCHARKER PROPALIS FOR EXTRACTING COLORICTAL TUNCAS: PROTIEN EIGMAPKER PROPALIS FOR PEDETRING COLORICTAL TUNCAS: PROTIEN EIGMAPKER PROPALIS FOR EXTENTION COLORICTAL TUNCAS: PROTIEN EIGMAPKER PROPALIS FOR EXTENTION COLORICTAL TUNCAS:
Noors Ds Noors Ds Noors Ds		JP JP CN		2017-502947 2017-552968 201780076307.1	21-Mar-2015 08-Apr-2016 06-Oct-2017				PROTEIN EROMARKER PROFILES FOR DETECTING COLORBECTAL TUMARS PROTEIN EROMARKER PARELL FOR DETECTING COLORBECTAL CANCER PROTEIN EROMARKER PARELL STOR DETECTING COLORBECTAL CANCER AND ADVANCED ADEROMA
Discern Da Discern Da Discern Da		JP CN IN		2019-518244 201910577840.7 201917017666	06-Oct-2017 02-Dec-2013 06-Oct-2017				PROTEIN BLOGGUERED PARKET KYR D'ETRETTING COLOMBETT LA CAMERS AON, ATVANCED ADBROMIA NEITROD FOR EVALUATION OF PRESENCE OF OR 1838 OF COLON TUNIORS. PROTEIN BROMAN REP PARELS FOR D'ETRETTING COLOMBET LA CAMER AON AUVANCED ADBROMIA.
Discers Dis Discers Dis Discers Dis		EA IN		247981 3-039.260 568300ELNP/2015	27-Mar-2015 05-Oct-2017 02-Dec-2013				PROTIEN HIGMARKER PROFELIS FOR DETECTING COLORBETTAL TUMORS. PROTIEN HIGMARKER PANELS FOR DETECTING COLORBETTAL CANCER AND ADVANCED ADENOMA. METIKOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLOR TEMORE.
Nicera Dx Nicera Dx Nicera Dx		US BK MX		62/857 636 62/830002195 9 MX/A/2015/006257	05-Jun-2019 06-Oct-2017 02-Dec-2013				Coffordia Carra Brohafter Barria. PRICTIEN BLOMARKER FANEL S FOR DETECTING COLORECTAL CANCER AND ADVANCED ADENIONA MITTHEO THE BY MALISATION OF PRESENCE OF OR RESK OF COLON TUMORS.
NiceraDx NiceraDx NiceraDx		MX MY		MX/a/2016/012691 Pt 2015/01416 Pt 2016/01748	2)-Mar-2015 02-Dec-2013 21-Sep 2016				PROTEIN BIOMARKER PROFILES FOR DEFECTING COLORECT AL TUMORS METHOD THE EVALUATION OF PRESIDENCE OF OR 185K OF SOLON TUMORS PROTEIN BIOMARKER PROFILES FOR DEFECTING COLORECT AL TUMORS
NicereDs NicereDs NicereDs		WO WO		PI 2017001497 PCT/US2013/012691 PCT/US2015/023187	08-Anr-2016 02-Dec-2013 27-May-2015				PROTEIN INCOMPRESE PARIEL PRIN DETECTING COLORECTAL CANCER METINGO FIRE PATALIZATION OF RESIDENCE OF OR MISK OF COLOR TRANSES PROTEIN BLOGGREGAR PROFILES FOR DETECTING COLORECTAL TURKES
Discern Ds Discern Ds Discern Ds		wo wo		PCT/US2016026773 PCT/US2017/025580 PCT/US2017/027051	08-Anr-2016 31-Mar-2017 11-Anr-2017				PROTEIN REGIGNARIES PARIELS FOR DETECTION COLORISETAL CANCER AND ADVANCED ADRIVANT SOMMARIZED ATALASES CORPERATION AND USE MASS SPECTROMOTIVES USA A ANALYSIS MERITICAN MASS SPECTROMOTIVES USA A NALYSIS MERITICAN SPECTROMORIAMENTS PARIES TO SECTION FOR CONTROLLED AND ADVANCES ATTENDED
Discern Dx Discern Dx		wo wo		PCT/US2617/055659 PCT/US2618/037417	06-Oct-2017 13-fun-2018				PROTEIN BROMARKER PANELS FOR DETECTING COLORECTAL CANCER AND ADVANCED ADENDMA. TANDEM-IDENTIFICATION ENGINE.
Discern Dix Discern Dix		wo wo	***************************************	PCT/LS2018/649594 PCT/LS2018/649583	05-Sep-2018 05-Sep-2018				AUTOMATED SAMPLE WORKEROW GATING AND DATA ANALYSIS WARKER MALLYSIS RIK (GLAUTY CORTING AND DESCRIP DETECTION MORET PAINES OF COLEMBITAL CANDE BIOMARKIES WETHERD AND SYSTEMS FOR DETECTION OF VIEW DISEASE

RECORDED: 10/18/2023

PATENT REEL: 065263 FRAME: 0687